

Supplementary Table 2. In-hospital clinical outcomes among three groups

	No. (%)		Unadjusted		Multivariate-adjusted		Propensity score-matched		IPW-adjusted	
			OR (95% CI)	p value ^a	OR (95% CI)	p value	OR (95% CI)	p value	OR (95% CI)	p value
Unchanged clopidogrel vs. P2Y12RI switching	4,674	1,399								
All-cause death	162 (3.5)	24 (1.7)	0.486 (0.315–0.750)	0.001	1.020 (0.467–2.227)	0.961	1.060 (0.544–2.065)	0.865	0.875 (0.653–1.173)	0.653
Cardiac death	138 (3.0)	16 (1.1)	0.380 (0.226–0.640)	<0.001	0.581 (0.231–1.464)	0.250	0.664 (0.297–1.484)	0.318	0.643 (0.445–0.931)	0.019
Non-fatal MI	9 (0.2)	11 (0.8)	4.108 (1.699–9.933)	0.002	4.186 (1.705–10.278)	0.002	2.511 (0.786–8.028)	0.120	3.184 (1.591–6.372)	0.001
Definite stent thrombosis	7 (0.1)	10 (0.7)	4.800 (1.824–12.633)	0.002	3.824 (1.420–10.299)	0.008	3.014 (0.814–11.157)	0.099	3.659 (1.689–7.926)	0.001
Stroke	35 (0.7)	8 (0.6)	0.762 (0.353–1.647)	0.588	0.872 (0.398–1.910)	0.731	0.888 (0.342–2.309)	0.808	0.966 (0.624–1.497)	0.879
MACEs	174 (3.7)	35 (2.5)	0.664 (0.459–0.959)	0.029	1.077 (0.660–1.759)	0.766	1.079 (0.629–1.850)	0.783	1.017 (0.787–1.315)	0.896
TIMI major bleeding	63 (1.3)	28 (2.0)	1.495 (0.954–2.342)	0.080	1.611 (0.987–2.631)	0.056	1.817 (0.962–3.431)	0.066	1.735 (1.300–2.315)	<0.001
TIMI minor bleeding	108 (2.3)	51 (3.6)	1.600 (1.140–2.244)	0.007	1.964 (1.364–2.829)	<0.001	2.082 (1.282–3.380)	0.003	1.946 (1.563–2.423)	<0.001
TIMI major or minor bleeding	151 (3.2)	66 (4.7)	1.483 (1.104–1.993)	0.011	1.813 (1.311–2.507)	<0.001	1.959 (1.284–2.988)	0.002	1.818 (1.504–2.197)	<0.001
NACEs	222 (4.7)	58 (4.1)	0.867 (0.646–1.165)	0.383	1.339 (0.923–1.941)	0.124	1.356 (0.885–2.078)	0.162	1.324 (1.085–1.615)	0.006
Unchanged potent P2Y12RIs vs. P2Y12RI switching	2,403	1,399								
All-cause death	60 (2.5)	24 (1.7)	0.682 (0.423–1.099)	0.137	0.310 (0.090–1.068)	0.064	0.579 (0.298–1.124)	0.106	0.637 (0.421–0.962)	0.032
Cardiac death	49 (2.0)	16 (1.1)	0.556 (0.315–0.981)	0.043	0.167 (0.037–0.748)	0.019	0.417 (0.182–0.957)	0.039	0.447 (0.265–0.754)	0.003
Non-fatal MI	9 (0.4)	11 (0.8)	2.108 (0.871–5.100)	0.105	2.344 (0.965–5.691)	0.060	2.512 (0.786–8.032)	0.120	2.546 (1.357–4.779)	0.004
Definite stent thrombosis	7 (0.3)	10 (0.7)	2.464 (0.936–6.488)	0.076	2.792 (1.056–7.383)	0.038	3.015 (0.814–11.162)	0.098	2.865 (1.423–5.766)	0.003
Stroke	3 (0.1)	8 (0.6)	4.601 (1.219–17.371)	0.023	4.179 (1.103–15.836)	0.035	6.024 (0.724–50.113)	0.097	3.733 (1.342–10.380)	0.012
MACEs	61 (2.5)	35 (2.5)	0.985 (0.647–1.501)	1.000	1.208 (0.672–2.171)	0.529	1.000 (0.565–1.771)	1.000	1.135 (0.808–1.594)	0.465
TIMI major bleeding	65 (2.7)	28 (2.0)	0.735 (0.469–1.150)	0.192	0.696 (0.432–1.122)	0.137	0.545 (0.318–0.934)	0.027	0.700 (0.514–0.954)	0.024
TIMI minor bleeding	92 (3.8)	51 (3.6)	0.950 (0.671–1.347)	0.860	0.920 (0.638–1.328)	0.658	0.775 (0.524–1.145)	0.200	0.950 (0.749–1.206)	0.674
TIMI major or minor bleeding	132 (5.5)	66 (4.7)	0.852 (0.629–1.153)	0.325	0.837 (0.605–1.157)	0.281	0.731 (0.515–1.037)	0.079	0.861 (0.699–1.059)	0.157
NACEs	117 (4.9)	58 (4.1)	0.845 (0.612–1.166)	0.336	0.816 (0.554–1.203)	0.305	0.732 (0.489–1.095)	0.129	0.879 (0.694–1.113)	0.284

Values are presented as number (%).

RI, receptor inhibitor; IPW, inverse probability weighting; OR, odds ratio; CI, confidence interval; MI, myocardial infarction; MACE, major adverse cardiovascular event; TIMI, thrombolysis in myocardial infarction; NACE, net adverse cardiovascular event.

^ap value < 0.0167 was considered statistically significant.